![]() |
Acta Pharmacologica Sinica 2007 April; 28 (4): 579-583; doi: 10.1111/j.1745-7254.2007.00517.x |
| Original Article | [ Full text ] |
| Effect of MDR1 gene polymorphism on progression of end-stage renal disease1 |
Wei-xia ZHANG2, Bing CHEN2, Wen ZHANG3, Nan CHEN3, Zi-cheng YU2, Wei-min CAI2,4 2Institute of Clinical Pharmacology and 3Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China |
Methods: Two hundred and eighty-four healthy Chinese controls and 244 Chinese patients with ESRD were involved in this study. Allele specific PCR and polymerase chain reaction-restriction fragment length polymorphism assay were used to determine the genotype MDR1 G1199A and C3435T, respectively.
Results: The genotype distribution of 3435CC, 3435CT, and 3435TT were 0.35, 0.50, and 0.15, respectively, in the control group and 0.38, 0.47, and 0.15 in the group with the ESRD patients. No variant allele 1199G>A was found in any of the patients. The value of serum creatinine for genotypes 3435CC, 3435CT, and 3435TT in the ESRD patients were 753.8±276.0 µmol/L, 849.6±342.2 µmol/L, and 987.0±512.0 µmol/L, respectively. The difference between 3435TT and 3435CC reached statistical significance (P<0.05).
|
Keywords: end-stage renal disease; multiple drug resistance gene 1; polymorphism |
| 1 Project supported by the National Natural Science Foundation of China (No 30271526) and the Foundation for the Author of National Excellent Doctoral Dissertation of China (No 200368). |
|
[ Full text ] |
Copyright©APS 2009 Add: 294 Tai-Yuan Road, Shanghai 200031, China Phn: 86-21-5492-2821 Fax: 86-21-5492-2823 E-mail: aps@mail.shcnc.ac.cn |